期刊文献+

国产右旋布洛芬缓释胶囊在大鼠体内的药动学及生物利用度研究 被引量:4

Pharmacokinetics and Bioavailability of Dexibuprofen Sustained Release Capsules in Rats
暂未订购
导出
摘要 目的考察自制和市售右旋布洛芬缓释胶囊在大鼠体内的药动学性质与生物等效性。方法建立反相高效液相色谱法,测定右旋布洛芬在血浆中的浓度,进行药动学和相对生物利用度研究。结果自制和市售右旋布洛芬缓释胶囊的主要药动学参数Cmax分别为(1 173.87±281.68),(1 186.06±268.79)μg.mL-1;AUC(0-t)分别为(4 276.53±578.59),(4 489.83±645.73)mg.L-1.h;AUC(0-∞)分别为(5 095.58±683.82),(5 466.37±753.35)mg.L-1.h;tmax分别为(1.33±0.26),(1.58±0.49)h;各参数间比较差异无统计学意义(P>0.05),以AUC(0-∞)计算自制右旋布洛芬缓释胶囊的相对生物利用度为(93.2±12.5)%。结论自制右旋布洛芬缓释胶囊与市售制剂之间生物等效。 Objective To investigate the pharmacokinetics and bioavailability of self-prepared dexibuprofen sustained release capsules and reference formulation in rats.Methods An RP-HPLC method was established to determine the concentration of dexibuprofen in plasma.Dexibuprofen sustained release capsule was prepared,and its pharmacokinetic parameters and bioavailability in SD rats were studied after oral administration.Results The pharmacokinetics parameters of dexibuprofen showed that Cmax was(1 173.87±281.68) and(1 186.06±268.79) μg·mL^-1,AUC(0-t)(4 276.53±578.59) and(4 489.83±645.73) mg·L^-1·h,AUC(0-∞)(5 095.58±683.82) and(5 466.37±753.35) mg·L^-1·h,tmax(1.33±0.26) and(1.58±0.49) h for self-prepared dexibuprofen sustained release capsules and reference formulation,respectively.There was no significant difference between the parameters of the two formulations(P0.05).The relative bioavailability of self-prepared dexibuprofen sustained release capsules to reference formulation is(93.2±12.5)%.Conclusion The results of statistical analysis show that self-prepared dexibuprofen sustained release capsules and reference formulation are bioequivalent.
出处 《医药导报》 CAS 北大核心 2012年第10期1291-1294,共4页 Herald of Medicine
关键词 右旋布洛芬 缓释胶囊 药动学 生物等效性 Dexibuprofen Sustained release capsules Pharmacokinetics Bioequivalence
  • 相关文献

参考文献8

  • 1KAEHLER S T, PHLEPS W, HESSE E. Dexibuprofen: pharmacology, therapeutic uses and safety [ J ]. Inflammopharmacology ,2003,11 (4) :371-383.
  • 2HARDIKAR M S. Chiral non-steroidal anti-inflammatory drugs-a review [J]. J Indian Med Assoc, 2008,106 ( 9 ) : 615-618.
  • 3MAYRHOFER F. Efficacy and long-term safety of dexibu- profen [ S ( + ) -ibuprofen ] : a short-term efficacy study in patients with osteoarthritis of the hip and a 1 -year tolerability study in patients with rheumatic disorders [ J ]. Clin Rheumatol,2001,20( Suppl 1 ) :22-29.
  • 4HAWEL R, KLEIN G, SINGER F, et al. Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip [ J ]. Int J Clin Pharmacol Ther,2003,41 (4) :153-164.
  • 5GOMEZ B J, CAUNEDO A, REDONDO L,et al. Modification of pepsinogen I levels and their correlation with gastrointestinal injury 'after administration of dexibuprofen, ibuprofen or diclofenac : a randomized, open-label, controlled clinical trial [ J ]. lnt J Clin Pharmacol Ther, 2006,44 ( 4 ) : 154-162.
  • 6YI H G,CHI M H,KIM Y I,et al. Formulation of a extended release tablet containing dexibuprofen [ J ]. Arch Pharm Res, 2008,31 ( 12 ) : 1637-1643.
  • 7SANTOS H, VEIGA F, PINA M E, et al. Compaction, com- pression and drug release properties of diclofenac sodium and ibuprofen pellets comprising xanthan gum as a sustained release agent[ J]. Int J Pharm,2005,295 (1-2) : 15-27.
  • 8YU C, HONG Y C, ZHANG H, et al. Determination of ibu- profen :in serum by RP-HPLC [ J ]. Chin J Phanna Anal, 1994,14(4) :34-36.

同被引文献25

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部